This study assessed the relationship between cancer survival, quality of life, and specific cancer symptoms among 11 different types of cancer.

The authors aimed to determine the risk of Alzheimer's disease in patients who underwent hormone therapy for prostate cancer. Results concluded that there is an association between hormone therapy and Alzheimer's development, particularly in patients who underwent hormone therapy for more than 12 months.

This study evaluated the outcomes of prostate cancer patients with persistently detectable levels of prostate-specific antigen (PSA) following radical prostatectomy (RP).

This study analyzed the health-related quality of life (HRQOL) in patients with metastatic castration-sensitive prostate cancer (MCSPC) after treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT). The study found that apalutamide plus ADT was well tolerated and improved survival compared to ADT alone in these patients.

The present study compared the effectiveness of two kinds of hormonal therapy in advanced prostate cancer (cancer that has spread beyond the prostate gland). These are intermittent hormonal therapy (IHT) and continuous androgen-deprivation therapy (ADT). In this study, IHT was similar to ADT in terms of survival, but showed better quality of life in patients with advanced prostate cancer (PCa).

This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment improved patients’ survival in these patients.

This study investigated the effects of salvage stereotactic radiotherapy (SSRT) in patients with prostate bed recurrence after prostate surgery. The main finding was that SSRT was effective at curing or delaying prostate cancer recurrence.

This study investigated whether adding apalutamide (erleada) to androgen-deprivation therapy (ADT) would improve survival in patients with prostate cancer. The authors concluded that adding apalutamide to ADT improved outcomes for these patients.

This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. 
They found that cancer survivors have a higher risk of CVD.

This article reviewed the guidelines for the continued care of prostate cancer survivors following successful treatment.